Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal Phase II Trial of Vismodegib in Advanced Basal Cell Carcinoma
2008-004945-27Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in basal cell carcinoma (BCC), sponsored by Genentech. Primary endpoint: Objective response rate. Started Mar 2009; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2008-004945-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004945-27.